Elon Musk says expects Neuralink to begin human trials in six months




  • In US
  • 2022-12-01 03:07:57Z
  • By Reuters
 

(Reuters) -Elon Musk said on Wednesday a wireless device developed by his brain chip company Neuralink is expected to begin human clinical trials in six months.

The company is developing brain chip interfaces that it says could enable disabled patients to move and communicate again. Based in the San Francisco Bay Area and Austin, Texas, Neuralink has in recent years been conducting tests on animals as it seeks U.S. regulatory approval to begin clinical trials in people.

"We want to be extremely careful and certain that it will work well before putting a device into a human but we've submitted I think most of our paperwork to the FDA and probably in about six months we should be able to upload Neuralink in a human," Musk said during a much-awaited public update on the device.

The event was originally planned for Oct. 31 but Musk postponed it just days before without giving a reason.

Neuralink's last public presentation, more than a year ago, involved a monkey with a brain chip that played a computer game by thinking alone.

Musk is known for lofty goals such as colonizing Mars and saving humanity. His ambitions for Neuralink, which he launched in 2016, are of the same grand scale. He wants to develop a chip that would allow the brain to control complex electronic devices and eventually allow people with paralysis to regain motor function and treat brain diseases such as Parkinson's, dementia and Alzheimer's. He also talks of melding the brain with artificial intelligence.

Neuralink, however, is running behind schedule. Musk said in a 2019 presentation he was aiming to receive regulatory approval by the end of 2020. He then said at a conference in late 2021 that he hoped to start human trials this year.

Neuralink has repeatedly missed internal deadlines to gain U.S. Food and Drug Administration (FDA) approval to start human trials, current and former employees have said. Musk approached competitor Synchron earlier this year about a potential investment after he expressed frustration to Neuralink employees about their slow progress, Reuters reported in August.

Synchron crossed a major milestone in July by implanting its device in a patient in the United States for the first time. It received U.S. regulatory clearance for human trials in 2021 and has completed studies in four people in Australia.

(Reporting by Rachael Levy in Washington, D.C.; Editing by Muralikumar Anantharaman)

COMMENTS

More Related News

As Tesla ignites an EV price war, suppliers brace for Musk seeking givebacks
As Tesla ignites an EV price war, suppliers brace for Musk seeking givebacks

Tesla Inc suppliers are bracing for pressure from Chief Executive Elon Musk and his team to cut their prices further after the electric car leader...

EU official pushes Musk for Twitter
EU official pushes Musk for Twitter's progress on new rules
  • US
  • 2023-02-01 11:38:58Z

A top European Union official told Elon Musk that Twitter needs to make progress in preparing for a new law aimed at curbing hate speech, misinformation and ...

Elon Musk
Elon Musk's Tesla tweet trial delves into investor damages
  • World
  • 2023-01-31 23:15:25Z

An Elon Musk tweet declaring he had the financing to take Tesla private in 2018 caused billions of dollars in investor damages after the deal collapsed...

DOJ requests Autopilot, FSD documents from Tesla
DOJ requests Autopilot, FSD documents from Tesla

The U.S. Department of Justice has asked Tesla for documents related to its branded Full Self-Driving and Autopilot advanced driver assistance systems, the...

Tesla to boost spending as plant expansions gather pace
Tesla to boost spending as plant expansions gather pace
  • US
  • 2023-01-31 11:30:29Z

The company, led by billionaire Elon Musk, forecast capital expenditure between $7 billion and $9 billion in 2024 and 2025. Some of the spending will go...

Leave a Comment

Your email address will not be published. Required fields are marked with *

Cancel reply

Comments

Top News: US